Multikinase inhibitors use in differentiated thyroid carcinoma

Multikinase inhibitors use in differentiated thyroid carcinoma

Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from tradit...

Timing of multikinase inhibitor initiation in differentiated thyroid cancer

There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for ...

Evaluation of Treatment of Differentiated Carcinoma of Thyroid.

The treatment of patient with differentiated carcinoma of thyroid consists of three stages, surgery, I 1.1.i ablation and hormone therapy. To avoid the problems mentioned in the article, initially the patient should have thyroid scan, T.1 , T4, thyroglobulin estimation and a chest x-ray, prior to surgery which should be carried out by a competent surgeon, in order that total thyroidectomy can b...

Emerging role of multikinase inhibitors for refractory thyroid cancer

Thyroid cancer incidence continues to increase, remaining the most common endocrine malignancy. The need for effective systemic therapies combined with high incidence of driver mutations and overexpression of molecular pathways make refractory thyroid cancer an ideal candidate for treatment with novel agents. Multikinase inhibitors have caused a paradigm shift in the treatment of patients with ...

[Prognostic factors in differentiated thyroid carcinoma].